Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Arbutus Biopharma to post earnings of ($0.09) per share and revenue of $2.54 million for the quarter.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $1.57 million during the quarter, compared to analysts' expectations of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Arbutus Biopharma Stock Performance
ABUS traded up $0.09 during midday trading on Tuesday, hitting $3.43. The company had a trading volume of 139,367 shares, compared to its average volume of 986,765. Arbutus Biopharma has a twelve month low of $2.63 and a twelve month high of $4.73. The company has a market capitalization of $655.82 million, a PE ratio of -7.92 and a beta of 1.45. The firm's 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.44.
Wall Street Analyst Weigh In
ABUS has been the topic of several analyst reports. Chardan Capital reiterated a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 28th. StockNews.com upgraded shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, March 29th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Arbutus Biopharma presently has an average rating of "Moderate Buy" and an average target price of $5.50.
View Our Latest Report on Arbutus Biopharma
About Arbutus Biopharma
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Stories
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
